---
layout: default
title: Lactic Acid
parent: Model Prediction Only (L5)
nav_order: 512
evidence_level: L5
indication_count: 10
---

# Lactic Acid
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **10** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

# Lactic Acid: From an Unspecified Original Indication to Atypical Coarctation of Aorta

## One-Sentence Summary

Lactic acid is marketed in Canada under three licences (DINs), but the regulatory record does not state its approved indication.
The TxGNN model predicts it may be effective for **atypical coarctation of aorta**, but **0 clinical trials** and **0 publications** currently support this prediction, so it rests on the model score alone.

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not recorded in the available regulatory data |
| Predicted New Indication | Atypical coarctation of aorta |
| TxGNN Prediction Score | 99.59% |
| Evidence Level | L5 (model prediction only) |
| Canada Market Status | ✓ Marketed |
| Number of DINs | 3 |
| Recommended Decision | Hold |

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available, and no original indication is recorded for lactic acid. It is therefore not possible to explain how its known use might carry over to the predicted condition.

Atypical coarctation of aorta is a structural congenital narrowing of the aorta. Nothing in the data links lactic acid to correcting or treating a structural vascular defect. The high score (99.59%) reflects a pattern in the knowledge graph. It does not reflect any biological or clinical finding, and no trial or publication was retrieved to back it. This should be treated as a low-plausibility, unsupported prediction.

The other top-ranked predictions look similar. Several are congenital malformations with no evidence. Where indirect literature exists (dry eye, esophageal disease, eye disease), it mostly describes lactate as a driver or biomarker of disease, not as a treatment.

## Clinical Trial Evidence

Currently no related clinical trials registered.

## Literature Evidence

Currently no related literature available.

## Canada Market Information

| DIN | Product Name |
|---------|------|
| 2274876 | PRISM0CAL |
| 2243095 | PRISMASOL 0 |
| 2277476 | PRISMASOL 4 |

Dosage form, manufacturer and approved indication text are not recorded for these licences.

## Safety Considerations

Please refer to the package insert for safety information.

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The prediction has no supporting trials or literature (L5), and the data show no plausible link between lactic acid and a structural congenital aortic defect. The two blocking gaps, missing safety labelling and missing mechanism of action, also prevent any safety screening.

**To proceed, the following is needed:**
- Health Canada package insert warnings and contraindications (obtain and parse the product monographs for the three DINs)
- Approved indication text and dosage forms for each DIN, to establish the original indication and administration route
- Mechanism of action data (for example, from the DrugBank API) to assess any biological link
- Any clinical or preclinical study testing lactic acid in aortic coarctation. Without one, this candidate should not advance.
- Consideration of other predicted indications only if direct therapeutic evidence emerges, since the current indirect evidence for dry eye, esophageal disease and eye disease points toward lactate as a pathogenic factor

*This report is for research reference only and does not constitute medical advice. Repurposing candidates require clinical validation before any application.*
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

